生物活性
Kongensin A 是一种从 Croton kongensis 中分离的天然产物。 Kongensin A 是一种有效的,共价的 HSP90 抑制剂,可阻断 RIP3 依赖性坏死病。Kongensin A 是一种有效的坏死性抑制剂和凋亡诱导剂,并具有潜在的抗坏死性和消炎性应用。
体外研究
Kongensin A (0-15 μM; 6 hours; HT29 cells) treatment induces caspase activation and apoptosis in multiple cancer cell lines in a dosage-dependent manner.
Kongensin A (0-15 μM; 24 hours; HT29 cells) treatment induces the degradation of RIPK1 and oncogenic kinases such as ERBB2, AKT, EGFR, and B-raf, and induces the up-regulation of HSP90A and HSP90B.
Kongensin A covalently binds to cysteine 420 in the middle domain of HSP90 and dissociates HSP90 from its cochaperone CDC37. The HSP90-CDC37 complex is required for RIP3 activation, KA blocks LPS/Smac mimetics/Z-VAD and RIP3 polymerization-induced cell death, in which cell death is dependent on RIP3 but not its upstream kinase RIP1.
Apoptosis Analysis
Cell Line: HT29 cells
Concentration: 0 μM, 2.5 μM, 5 μM, 15 μM
Incubation Time: 6 hours
Result: Induced caspase activation and apoptosis in a dosage-dependent manner.
Western Blot Analysis
Cell Line: HT29 cells
Concentration: 0 μM, 2.5 μM, 5 μM, 15 μM
Incubation Time: 24 hours
Result: Induced the degradation of RIPK1 and oncogenic kinases such as ERBB2, AKT, EGFR, and B-raf, and induced the up-regulation of HSP90A and HSP90B.
Concentration:
0 μM, 2.5 μM, 5 μM, 15 μM
Result:
Induced caspase activation and apoptosis in a dosage-dependent manner.
Concentration:
0 μM, 2.5 μM, 5 μM, 15 μM
Result:
Induced the degradation of RIPK1 and oncogenic kinases such as ERBB2, AKT, EGFR, and B-raf, and induced the up-regulation of HSP90A and HSP90B.